CanSinoBIO Q3 revenue up 27% on new vaccine launches and global expansion
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
prwire.com.au
whatech.comCanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth
Hong Kong, Oct 27, 2026 - (ACN Newswire) - On October 27, 2026, CanSino Biologics Inc. (HKEX: 06185; SSE: 688185) released its third-quarter financial report for 2026. For the nine months ended September 30, 2026, the company reported revenue of approximately RMB 882 million, an increase of 27.40% year-on-year. Net profit attributable to shareholders reached approximately RMB 16.29 million, an increase of 12.82% year-on-year. Net loss attributab…
CanSinoBIO Q3 revenue up 27% on new vaccine launches and global expansion
Hong Kong, October 27, 2026: CanSino Biologics Inc. reported a 27.40% year-on-year increase in revenue to approximately RMB 882 million for the nine months ended September 30, 2026, as the company accelerated commercialization across multiple vaccine products. Net profit attributable to shareholders rose 12.82% to about RMB 16.29 million, while net loss excluding non-recurring gains […]
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
